Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9^th Edition of the Paris NASH meeting, where a select group of international experts gather each year at the prestigious Institut Pasteur in Paris to discuss the latest scientific and clinical research developments in non-alcoholic steatohepatitis (NASH) and its complications, including liver cirrhosis. This year, Galectin Therapeutics, in collaboration with HistoIndex of Singapore, will present a poster on the use of artificial intelligence to better explore the complex histology of liver cirrhosis resulting from NASH and highlight potential differences between lean cirrhotic patients and overweight/obese cirrhotic patients.¹

Pol Boudes, MD, Chief Medical Officer of Galectin Therapeutics, commented: “Artificial Intelligence is an interesting tool that can improve the definition, description, and understanding of architectural changes in the liver tissue of cirrhotic patients. Current histology methods are not precise enough to be clinically relevant to stage the cirrhotic process and, consequently, are not generally used in clinical practice. Conventional histology is also not granular enough and not quantitative enough to evaluate the efficacy of candidate drugs. We are happy to contribute to the scientific progress in this field by sharing our data collected in our previous phase 2 cirrhosis program and by using the innovative technology that our colleagues at HistoIndex have developed.”

Dr. Boudes continued: “The Paris meeting is another opportunity to discuss our innovative pivotal program regarding patients with portal hypertension that results from NASH cirrhosis. We are using an innovative clinical outcome criteria – the prevention of esophageal varices, a direct consequence of portal hypertension – to evaluate the efficacy of belapectin. We have now collected more than 500 video recordings of esophago-gastro-duodeno endoscopies in this patient population and, at the appropriate time, we will be very excited to share the unique set of data we have collected with the medical, patient, and regulatory communities.”